Acquired AmpC type beta-lactamases: An emerging problem in Italian long-term care and rehabilitation facilities

New Microbiologica

Volumn 30, Issue 3, 2007, Pages 295-298

  Migliavacca, Roberta ^a   Nucleo, Elisabetta ^a   D'Andrea, Marco M ^b   Spalla, Melissa ^c   Giani, Tommaso ^b   Pagani, Laura ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

CMY 16; Long term care and rehabilitation facilities; Proteus mirabilis

Indexed keywords

AMPC BETA LACTAMASES; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL GENE; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECT; GENETICS; GRAM NEGATIVE INFECTION; HUMAN; ITALY; LONG TERM CARE; METABOLISM; MICROBIOLOGY; MULTICENTER STUDY; PROTEUS MIRABILIS; PULSED FIELD GEL ELECTROPHORESIS; REHABILITATION CENTER; SPECIES DIFFERENCE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORINS; CEPHAMYCINS; CHROMOSOMES, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; GENES, BACTERIAL; HUMANS; ITALY; LONG-TERM CARE; PROTEUS INFECTIONS; PROTEUS MIRABILIS; REHABILITATION CENTERS; SPECIES SPECIFICITY;

MIRABILIS; PROTEUS MIRABILIS;

EID: 34547940831     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. ALVAREZ, M., TRAN, J.H., CHOW, N., JACOBY, G.A. (2004). Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. Antimicrob. Agents Chemother. 48, 533-537.
2. Bidet, P., Verdet C., Gautier V., Bingen E., and Arlet G. (2005). First description of DHA-1 AmpC β-lactamase in Proteus mirabilis. Clin. Microbiol. Infect. 11, 591-592.
3. D'ANDREA, M., NUCLEO E., FLUZZARO F., GIANI T., MIGLIAVACCA R., VAILATI F., KROUMOVA V., PAGANI L. AND ROSSOLINI G.M. (2006). CMY-16, a novel acquired AmpC-type β-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from Northern Italy. Antimicrob. Agents Chemother. 50, 618-624.
4. DECRE, D., VERDET C., RASKINE L., BLANCHARD H., BURGHOFFER B., PHILIPPON A., SANSON-LE-PORS MJ., PETIT JC, AND ARLET G. (2002). Characterization of CMY-type β-lactamases in clinical strains of Proteus mirabilis and Klebsiella pneumoniae isolated in four hospitals in the Paris area. J. Antimicrob. Chemother. 50, 681-688.
5. GIRLICH, D., KARIM A., SPICQ C., AND NORDMANN P. (2000). Plasmid-mediated cephalosporinase ACC-1 in clinical isolates of Proteus mirabilis and Escherichia coli. Eur. J. Clin. Microbiol. Infect. Dis. 19, 893-895.
6. LLTERACKA, E., EMPEL J., BARANIAK A., SADOWY E., HRYNIEWICZ W., AND GNIADKOWSKI M. (2004). Four variants of the Citrobacter freundii AmpC-type cephalosporinases, including novel enzymes CMY-14 and CMY-15, in a Proteus mirabilis clone widespread in Poland. Antimicrob. Agents Chemother. 48, 4136-4143.
7. LIVERMORE, DM. (1995). β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8, 557-584.
8. MIRIAGOU, V., TZOUVELEKIS L.S., VILLA L., LEBESS E., VATOPOULOS A.C., CARATTOLI A., AND TZELEPI E.. (2004). CMY-13, a novel inducible cephalosporinase encoded by an Escherichia coli plasmid. Antimicrob. Agents Chemother. 48, 3172-3174.
9. MULVEY, M.R., BRYCE E., BOYD D.A., OFNER-AGOSTINI M., LAND A.M., SIMOR A.E., PATON S. (2005). Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob. Agents Chemother. 49, 358-365.
10. NAAS, T. AND NORDMANN P. (1999). OXA-type β-lactamases. Curr. Pharm. Des. 5, 865-879.
11. NAKANO, R., OKAMOTO R., NAKANO Y., KANEKO K., OKITSU N., HOSAKA Y., AND INOUE M. (2004). CFE-1, a novel plasmid-encoded AmpC β-lactamase with an ampR gene originating from Citrobacter freundii. Antimicrob. Agents Chemother. 48, 1151-1158.
12. NAVARRO, F., PEREZ-TRALLERO E., MARIMON J.M., ALIAGA R., GOMARIZ M., AND MIRELIS B. (2001). CMY-2-producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999-December 2000). J. Antimicrob. Chemother. 48, 383-389.
13. PAPANICOLAOU, G.A., MEDEIROS A.A., AND JACOBY G.A. (1990). Novel plasmid mediated β-lactamase (MIR-1) conferring resistance to oxyimino- and β-methoxy β-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 34, 2200-2209.
14. PITOUT, J.D., THOMSON K.S., HANSON N.D., EHRHARDT A.F., MOLAND E.S., AND SANDERS CC. (1998). β-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa. Antimicrob. Agents Chemother. 42, 1350-1354.
15. Philippon, A., Arlet G., and Jacoby G.A. (2002). Plasmid-determined AmpCtype β-lactamases. Antimicrob. Agents Chemother. 46, 1-11.
16. RHIMI-MAHJOUBI, F., BERNIER M., ARLET G., JEMAA Z.B., JOUVE P., HAMMAMI A., AND PHILIPPON A. (2002). Identification of plasmid-encoded cephalosporinase ACC-1 among various enterobacteria (Klebsiella pneumoniae, Proteus mirabilis,Salmonella) isolated from a Tunisian hospital (Sfax 997-2000). Pathol. Biol. 50, 7-11.
17. TSAO, S.G., BRUNK, C.F., AND PEARLMAN, R.E. (1983). Hybridization of nucleic acids directly in agarose gels. Anal Biochem. 131:365-372.
18. Antimicrob. Agents Chemother. 43, 1350-1357.
19. YONG, D., LIM Y., SONG W., CHOI YS., PARK D.Y., LEE H., YUM J.H., LEE K., KIM J.M., AND CHONG Y. (2005). Plasmid-mediated, inducible AmpC β-lactamase (DHA-1)-producing Enterobacteriaceae at a Korean hospital: wide dissemination in Klebsiella pneumoniae and Klebsiella oxytoca and emergence in Proteus mirabilis. Diagn. Microbiol. Infect. Dis. 53, 65-70.